跳至主要内容
临床试验/NCT00996177
NCT00996177已完成4 期

Comparison of Transdermal Fentanyl PCA and IV Morphine PCA in the Management of Postoperative Pain Control

Janssen-Cilag International NV0 个研究点目标入组 657 人开始时间: 2004年6月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
657
主要终点
Patient's global assessment of pain control (poor, fair, good, excellent) 24 hours after start of study treatment

研究概览

简要总结

The purpose of this study is to evaluate the effectiveness and safety of a patient-controlled system to deliver fentanyl compared with a patient-controlled intravenous system to deliver morphine in the management of postoperative pain.

详细描述

This is a randomized (study drug assigned by chance), open-label (all people involved know the identity of the intervention) study to evaluate the clinical use, safety and ease of care of two patient-controlled analgesia (PCA) systems to deliver pain medication either through the skin or intravenously. The fentanyl hydrochloride PCA system, which delivers the medication through the skin, and morphine intravenous (IV)- PCA, which requires injection into a vein, are used for management of moderate to severe acute pain in postoperative patients who have undergone elective major abdominal or orthopedic surgery. These patients, who are expected to require postoperative pain relief with strong opioids for at least 24 hours, will control the delivery of medication for up to 3 days. Assessment of effectiveness include: patient's global assessment of pain control (poor, fair, good, excellent); Pain Intensity, measured on a visual numerical rating scale from 0 to 10, where 0 means no pain and 10 means the worst possible pain; Ease-of-Care questionnaires including Patient Ease-of-Care questionnaire, Nurse Ease-of-Care questionnaire, and Physical Therapist Ease-of-Care questionnaire; and, total number of doses delivered by patients in the fentanyl transdermal PCA or morphine IV PCA treatment groups. Safety evaluations include vital signs (pulse, blood pressure) and oxygen saturation, respiratory function, and the incidence of adverse events. The study hypothesis is that fentanyl transdermal PCA is not inferior to morphine IV PCA treatment in patient's global assessment of method of pain control during the first 24 hours after surgery. Transdermal PCA: 40 micrograms fentanyl per on-demand dose, each delivered over 10 minutes for a maximum of 6 doses/hr for 24 hours (maximum of 80 doses, 3.2milligrams). Morphine IV PCA: morphine doses with a maximum of 20 milligrams per 2 hours for 24 hours (maximum 12 doses, 240 milligrams).

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients who meet the criteria of American Society of Anesthesiology (ASA) pre-operative physical status I, II, or III
  • Patients expected to have moderate or severe pain after a major abdominal or orthopedic procedure
  • Patients expected to remain hospitalized for at least 24 hours postoperatively

排除标准

  • Known allergy or hypersensitivity to fentanyl, morphine, or to skin adhesives
  • Known or suspected to be dependent on strong opioids or to have abused any drug substance or alcohol
  • Severe respiratory symptoms
  • Chronic pain disorder
  • Pregnant or nursing women, or those lacking adequate contraception

研究组 & 干预措施

IONSYS

Experimental

IONSYS (fentanyl HCl) Iontophoretic TransdermalSystem

干预措施: IONSYS (fentanyl HCl) Iontophoretic TransdermalSystem (Drug)

Patient-Controlled Analgesia

Active Comparator

IV Morphine Patient-Controlled Analgesia (IV PCA)

干预措施: IV Morphine Patient-Controlled Analgesia (IV PCA) (Drug)

结局指标

主要结局

Patient's global assessment of pain control (poor, fair, good, excellent) 24 hours after start of study treatment

时间窗: 24 hours after randomization (24 hours after either the first transdermal iontorphoretic system was applied or 24 hours after the intravenous access for the morphine solution was applied).

次要结局

  • Assessment of pain control by patient and doctor(At 24, 48, and 72 hours after randomization)
  • Pain Intensity, vital signs, and oxygen level in the blood(Hourly through 8 hours and then every 4 hours after randomization)
  • Incidence of adverse events(Throughout study)

研究者

申办方类型
Industry
责任方
Sponsor

相似试验